Floatz logo

Loxo-435

Urinary Bladder Neoplasm

Eli Lilly and CompanyUNKNOWNPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Urinary Bladder Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Merck Sharp & Dohme LLC
Phase 2BB
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Eli Lilly and Company
Phase 2BB
Cis-Diamminedichloroplatinum Ii
Merck Sharp & Dohme LLC
Phase 2BB
Pembrolizumab
Eli Lilly and Company
Phase 2BB
Nivolumab
Ikena Oncology
Phase 2B

View all 36 →

Same molecule, other indications

Loxo-435 is also rated in:

ureter neoplasmActive
CC
Indicative · Phase 1
43 / 100
View asset →
metastatic neoplasmActive
C
Indicative · Phase 1
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →